市場調査レポート
商品コード
1439662
血液濃縮器 - 世界市場の考察、競合情勢、市場予測(2030年)Hemoconcentrators - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
血液濃縮器 - 世界市場の考察、競合情勢、市場予測(2030年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の血液濃縮器の市場規模は、2023年に1,163万米ドル、2030年までに1,404万米ドルに達し、2024年~2030年の予測期間にCAGRで3.24%の成長が見込まれます。市場は、心血管障害の負担の増加、老年人口の増加、各国の政府による取り組みの増加、血液濃縮器の安全性、入手性、使いやすさの向上への注目の高まりなどの要因によって成長が見込まれており、予測期間(2024年~2030年)に血液濃縮器市場の収益が大きく伸びる見込みです。
血液濃縮器の市場力学
血液濃縮器市場の注目すべき促進要因の1つは、心血管疾患の有病率の上昇です。
世界保健機関(WHO)(2022)のデータによると、心血管疾患は毎年約1,790万人の命に影響を与える世界最大の死因と考えられています。バイパス手術を必要とする心血管疾患には、主に冠動脈疾患、大動脈弁狭窄症、浮腫などの疾患が含まれます。
World Heart Federation(2019)による別の調査では、2030年までに心血管疾患により世界で2,300万人以上の命が影響を受けると推定されています。
心血管疾患の罹患率の増加は、不健康なライフスタイル、タバコの使用、高血圧、糖尿病、飲酒、肥満などの心血管疾患の危険因子の増加と関連している可能性があります。
例えば、Institute for Health Metrics and Evaluation(2023)によると、世界の喫煙者数は2019年に11億人に増加し、新規喫煙者の90%が25歳までに依存症になっています。
WHO(2023)によるもう1つの興味深い統計では、高血圧症の患者数が1990年から2019年にかけて倍増し、12億8,000万人に達したことが引用されています。
上記の危険因子の増加は、今後数年間に行われるバイパス手術の需要を増加させ、その結果、血液濃縮器の需要を高めます。
さらに、心血管疾患を発症しやすい老年人口の増加が、血液濃縮器市場の成長をさらに加速させる見通しです。WHO(2023)が提供したデータによると、2020年に世界中で約10億人が60歳以上でした。上記の資料は、2050年までに60歳以上の老年人口が倍増し、約21億人になると予測しています。また、80歳以上の人口は2020年~2050年に3倍に増え、4億2,600万人に達すると推定されています。
したがって、上記の要因が血液濃縮器市場の成長を加速させると予測されます。
しかし、熟練した専門家の不足や手術中の合併症が、血液濃縮器市場の抑制要因になる可能性があります。
COVID-19パンデミックは、ロックダウン、国境閉鎖、その他の製造、供給、輸入、輸出などの血液濃縮器市場に関連する活動の混乱につながったため、最初の数ヶ月間は血液濃縮器市場の成長に若干マイナスの影響を与えました。また、COVID-19の原因物質であるSARS-CoV-2ウイルスの蔓延の恐れや、パンデミックにまつわる不確実性のために、世界の多くの国が緊急時を除いて外来手術センター(ASC)の閉鎖を余儀なくされました。しかし、医療部門を含む産業全体の活動再開が血液濃縮器市場を押し上げており、2024年~2030年の予測期間における成長を促進する見込みです。
血液濃縮器市場のセグメント分析
血液濃縮器市場の製品タイプセグメントでは、小児用血液濃縮器カテゴリが2022年に71%の最高収益シェアを占めました。
心臓病を患う小児患者の増加が、小児用血液濃縮器の成長をもたらした主な理由です。NHS(2022)によると、英国では100人に1人の赤ちゃんが先天性心疾患を持って生まれています。
米国疾病予防管理センター(2022)の発表によると、心臓に欠陥を持って生まれた赤ちゃんの約4人に1人が重症先天性心疾患(CHD)です。
当レポートでは、世界の血液濃縮器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
Hemoconcentrators Market By Product Type (Pediatric Hemoconcentrators And Adult Hemoconcentrators), By End-User (Hospitals And Ambulatory Surgical Centres), and by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to a surge in the cases of cardiovascular diseases and growing burden of geriatric population globally
The global hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030. The hemoconcentrators market is slated to witness growth owing to factors such as the rising burden of cardiovascular disorders, the rising geriatric population, the increasing number of government initiatives by countries, and the growing focus on improving the safety, affordability, and usability of hemoconcentrators is expected to result in appreciable revenue growth in the hemoconcentrators market during the forecast period (2024-2030).
Hemoconcentrators Market Dynamics:
One of the noteworthy drivers of the hemoconcentrators market is the rise in the prevalence of cardiovascular diseases.
As per the data provided by the World Health Organization (WHO) 2022, cardiovascular disorders are considered the leading cause of death worldwide affecting about 17.9 million lives every year. Cardiovascular diseases requiring bypass surgeries mainly include disorders such as coronary artery disease, aortic stenosis, and edema, among others.
In another study by the World Heart Federation in the year 2019, it had estimated that more than 23 million lives will be affected globally owing to cardiovascular disorders by the year 2030.
The increase in the rates of cardiovascular diseases can be linked to an increase in the risk factors for cardiovascular diseases such as unhealthy lifestyle, tobacco usage, hypertension, diabetes, alcohol consumption, obesity, and others.
For instance, according to the Institute for Health Metrics and Evaluation (2023), the number of smokers worldwide increased to 1.1 billion in 2019, where 90% of all new smokers became addicted by the age of 25.
Another interesting statistic by the WHO (2023), quoted that the number of people living with hypertension doubled to 1.28 billion from 1990-2019.
The increase in the abovementioned risk factors will increase the demand for more bypass surgeries to take place in the upcoming years, thus raising the demand for hemoconcentrators.
Additionally, the rising geriatric population prone to the development of cardiovascular diseases is further going to accelerate the growth of the hemoconcentrators market. According to the data provided by the WHO (2023), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.
Thereby, the above-mentioned factors are expected to accelerate the growth of the hemoconcentrators market.
However, the dearth of skilled professionals and complications during surgery may act as restraining factors for the hemoconcentrators market.
The COVID-19 pandemic had a slightly negative impact on the market growth of hemoconcentrators during the initial few months owing to the lockdown impositions, border closures, and others leading to the disruption in the manufacturing, supply, import, export, and other related activities of the hemoconcentrators market. Also, owing to the fear of the spread of the SARS-CoV-2 virus which is the causative agent for COVID-19, and uncertainties revolving around the pandemic, many countries across the world were forced to close down ambulatory surgical centers (ASCs) except in case of emergencies. However, the resumption of activities across industries including the healthcare sector has been uplifting the hemoconcentrators market and will drive growth during the forecast period from 2024-2030.
Hemoconcentrators Market Segment Analysis:
Hemoconcentrators Market by Product Type (Pediatric Hemoconcentrators and Adult Hemoconcentrators), End-user (Hospitals and Ambulatory Surgical Centres), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the hemoconcentrators market, the pediatric hemoconcentrators category held the highest revenue share of 71% in 2022.
The increasing number of pediatric patients with heart diseases is the main reason responsible for the growth of pediatric hemoconcentrators. According to NHS 2022, one in a hundred babies are born with congenital heart disease in the UK.
As per the Centers for Disease Control and Prevention, 2022, about 1 in 4 babies born with a heart defect have a critical congenital heart defect (CHD).
The increasing importance of pediatric coronary artery bypass surgery (PCABS) for congenital heart disease in infants and children undergoing modern cardiac surgical procedures, because of its life-saving potential in unsuccessful coronary transfer operations is going to increase the demand for pediatric hemoconcentrators.
Due to the small size and low weight of pediatric patients among other factors, performing bypass surgery in infants and neonates is complicated. Pediatric hemoconcentrators help in reducing inflammatory cytokines and correcting electrolyte and acid-base imbalances, limit early postoperative RBCs transfusions, reduces swelling of the heart, and facilitate the closing of surgical incision for better outcome of pediatric cardiac surgery.
For example, CAPIOX® HC05 Hemoconcentrators by Terumo Corporation is a type of pediatric Hemoconcentrator that efficiently concentrates blood using a polysulfone membrane material at a high ultrafiltration rate.
Therefore, owing to the above-mentioned factors the pediatric hemoconcentrators category is expected to witness substantial growth in the overall hemoconcentrators market during the given forecast period.
North America is expected to dominate the overall Hemoconcentrators Market:
Among all the regions, North America held the largest share of 45% in the hemoconcentrators market in 2022.
This domination is owing to the surging prevalence of cardiovascular disorders such as heart failure, congenital heart disease, hypertension, and others, the growing government initiatives in the cardiovascular sector in the United States, and the presence of key players in the region is expected to propel the overall market growth.
According to the latest study conducted by the Centres for Disease Control and Prevention (CDC), one person dies every 34 seconds in the United States from cardiovascular disease. Also, as per the same source, about 697,000 people in the United States died from heart disease in 2020, in the United States and about 20.1 million adults aged 20 and older had coronary artery disease (CAD). The mortality rate can be controlled by treating or managing the disease through surgical procedures such as cardiac bypass surgery, ultimately increasing the demand for hemoconcentrators.
As per the above-mentioned source, congenital heart defects are the most common type of birth defect in the United States, affecting nearly 1% (about 40,000) of births per year. The American Heart Association projected that by 2035, more than 130 million US adults will have some type of heart disease.
Moreover, the increasing prevalence of risk factors for cardiovascular diseases such as hypertension, obesity, age, arteriosclerosis, and others will in turn drive the market for hemoconcentrators. As per the source, Million Heart, 2022, high blood pressure is the most prevalent heart disease in the US, as almost half of the population had been diagnosed with hypertension, in 2020.
Therefore, the above-mentioned factors are going to bolster the North America hemoconcentrators markets.
Hemoconcentrators Market Key Players:
Some of the key market players operating in the Hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO, STERIS, Chalice Medical Ltd., and others.
Recent Developmental Activities in the Hemoconcentrators Market:
In June 2022, STERIS plc completed the acquisition of Cantel Medical which was the parent company of Medivators Inc. and Minntech, leading manufacturers of hemoconcentrators.
Key Takeaways from the Hemoconcentrators Market Report Study
Market size analysis for current hemoconcentrators market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hemoconcentrators market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years.
Key companies dominating the global hemoconcentrators market.
Various opportunities available for the other competitor in the hemoconcentrators market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current hemoconcentrators market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for hemoconcentrators market growth in the coming future?
Target Audience who can be benefited from this Hemoconcentrators Market Report Study
Hemoconcentrators providers
Research organizations and consulting companies
Hemoconcentrators -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in hemoconcentrators
Various end users who want to know more about the hemoconcentrators market and the latest technological developments in the hemoconcentrators market.
Frequently Asked Questions for the Hemoconcentrators Market:
A hemoconcentrator is an ultrafiltration device consisting of semipermeable membrane fibers that remove plasma water and solutes. Blood passes through fibers of a microporous membrane, and since the hydrostatic pressure inside the fibers is higher than outside, effluent fluid can pass through the membrane and be drained.
The global hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030.
The hemoconcentrators market is expected to grow significantly owing to factors such as the rising burden of cardiovascular disorders, the rising geriatric population, and the increasing number of government initiatives by countries, among others during the given forecast period (2024-2030).
Some of the key market players operating in the hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO, STERIS, Chalice Medical Ltd., and others.
North America is expected to dominate the overall hemoconcentrators market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a large number of people suffering from cardiovascular diseases along with the rising geriatric population in the region. In addition, it is a highly potent market in terms of technological developments and launches along with the presence of key market players among other factors in the region.